A Schistosoma japonicum vaccine expression vector secreted and expressed by attenuated Salmonella and its application

A Salmonella, secretion and expression technology, applied in the field of Schistosoma japonicum vaccine expression vector, can solve the problems of limiting the effective presentation of antigens, and achieve the effects of high-efficiency secretion, high-efficiency expression and low cost

CN102277373AActive Publication Date: 2011-12-14NANJING UNIV
2 Cites 5 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2011-12-14

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of biotechnology and particularly relates to a schistosoma japonica vaccine salmonella secretion expression vector, which is a recombinant salmonella expression vector that is controlled by a bacterial promoter, guided by effector protein secreted by salmonella and secretion signal of the effector protein and used for secretion expression of schistosoma japonica antigen. The schistosoma japonica vaccine salmonella secretion expression vector can induce secretion expression of a schistosoma japonica vaccine in a hypoxic microenvironment in antigen presenting cells, can exist in vivo stably and continuously and is insusceptible to being lost. The schistosoma japonica vaccine salmonella secretion expression vector, by using an attenuated strain as a carrier, can perform the antigen carrying of the recombinant vaccine representing bacteria by means of oral taking. The schistosoma japonica vaccine salmonella secretion expression vector can be used for preparing schistosoma japonica vaccine for oral taking for preventing and treating schistosomiasis.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biological technology, and in particular relates to an expression vector of a schistosoma japonicum vaccine secreted and expressed by attenuated Salmonella and its application. Background technique

[0002] Schistosomiasis is a zoonotic parasitic disease that seriously endangers the health of humans and livestock. About 600 million people around the world live in schistosomiasis-endemic areas, 200 million people are infected, 120 million people have clinical symptoms, and the annual death toll reaches dozens Ten thousand. Since the development of the special drug praziquantel, the prevalence of schistosomiasis has been alleviated through group chemotherapy, but the spread of schistosomiasis is still continuing, and the number of patients is still increasing. Moreover, the resistance to chemical drugs such as praziquantel also greatly affects the prevention and control of schistosomiasis (McManus DP, Clin Microbiol...

Examples

Embodiment Construction

[0031] Taking the Schistosoma japonicum bivalent antigen sj23LHDGST (the large hydrophilic region of the sj23 molecule and the fusion protein of GST) as the delivery antigen as an example:

[0032] 1. Construction of secretory expressed vaccine vectors:

[0033]Antigen molecule sj23LHD-GST is secreted by Salmonella type Ⅲ secretion system and hemolysin secretion system respectively.

[0034] a) Construction of type III secretion expression vector: through the N-terminal 1-104 amino acids of type III secretion effector molecule sopE (sopE 1-104 ) is coupled with the antigen molecule sj23LHD to realize its secretion; the Escherichia coli nitrate reductase (nirB) promoter is used to express the type III secreted antigen. The nirB promoter was obtained by PCR method: the primer sequences were: P1: 5'-cccctcgagggttaccggcccgatcg-3'; P2: 5'-cccggatccaccgcctaccttaacgattc-3'; 50 ng of Escherichia coli genomic DNA was used as a template. The obtained fragments had XhoI and BamHI restr...